Cestocur

Quick links to important sections

Cestocur

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cestocur

Quick Facts about Cestocur

Property Description
Active ingredient Praziquantel
Form Oral film-coated tablet
Pharmacological class Anthelmintic drug
Common use Treatment of parasitic flatworm infections
Origin Synthetic (Pyrazino-isoquinoline derivative)

Cestocur: Definition, Active Ingredient, and Origin

Cestocur is a pharmaceutical product defined by its sole active component, Praziquantel, an active substance that has been clinically recognized for decades of use in antiparasitic therapy. This medication is a synthetic substance, belonging to the pyrazino-isoquinoline derivative class of chemical compounds. It is formulated as a single-component drug, presented as an oral film-coated tablet, a form commonly used for systemic treatments.

The oral route of administration allows the Praziquantel to be systematically absorbed, enabling it to reach sites of infestation throughout the body. The synthetic nature of the drug guarantees a consistent, standardized preparation, which is crucial for reliable systemic drug therapy. Its status as a prescription-only medication underscores the requirement for professional oversight during its use.

What Pharmacological Class Does Praziquantel Belong To?

The definitive classification for Cestocur, based on its active agent Praziquantel, is as an anthelmintic drug. This pharmacological category is reserved for medications used to treat parasitic worm infections. Praziquantel is specifically renowned for its high efficacy against cestodes (tapeworms) and trematodes (flukes), serving as an essential antiparasitic agent globally.

Praziquantel has been included on the World Health Organization's (WHO) Model List of Essential Medicines since 1979 for treating major parasitic diseases. This positioning reflects its importance and effectiveness in public health for managing specific parasitic flatworm infections. Praziquantel is used for schistosomiasis and most foodborne trematode infections. This medicine is crucial for eliminating parasitic flatworms from the body, supporting a general use scenario where an anthelmintic is required to clear these specific types of infestation.

What side effects are possible with Cestocur?

Possible Side Effects and Safety Information

The safety profile for Cestocur, which contains the active ingredient Praziquantel, is formally defined in regulatory documents based on clinical use and documented adverse reactions. These effects are generally classified by frequency and grouped according to the specific body systems affected.

Adverse Reactions Classified by Frequency

Adverse reactions are officially grouped by their incidence rates based on regulatory classifications, such as those established by the European Medicines Agency (EMA) and other authorities.

Classification Examples of Documented Effects
Common (up to 1 in 10 patients) Headache, dizziness, abdominal pain, nausea, vomiting, somnolence, fever, malaise, pruritus (itching).
Uncommon (up to 1 in 100 patients) Diarrhea, asthenia (weakness).
Rare (up to 1 in 1,000 patients) Myalgia (muscle pain), rash.

These effects are frequently reported in the Nervous System and Gastrointestinal System-Organ Classes and are often transient (short-lived) and related to the patient’s initial parasite burden.

Serious Safety Considerations

The regulatory profile notes that serious adverse events, including reports of seizures and cardiac arrhythmias, have been documented. The potential for severe hypersensitivity reactions is also recognized. For laboratory findings, a transitory, generally mild elevation of liver enzymes (transaminases) may be observed.

Specific Safety Constraints

Cestocur is strictly contraindicated in patients diagnosed with ocular cysticercosis due to the risk of irreversible damage to the eye. Furthermore, safety constraints include the risk of therapeutic failure when Praziquantel is co-administered with strong Cytochrome P450 3A4 (CYP3A4) inducers, as this can lead to critically low drug concentrations. Specific safety statements are also provided for patients with severe hepatic impairment, who require close monitoring due to potentially increased systemic exposure.

Overdose and Emergency Response

A Cestocur (Praziquantel) overdose is officially documented to present with several clinical manifestations. These include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and anorexia. Central Nervous System (CNS) effects are also recognized, commonly presenting as headache, dizziness, fatigue, and somnolence. Laboratory findings may show transient elevation of liver enzymes.

Of greater concern are severe neurological outcomes associated with excessive exposure, which may involve convulsions or loss of consciousness. Due to the potential for these serious effects, regulatory authorities explicitly mandate that individuals experiencing a suspected overdose must seek immediate medical attention or contact emergency services without delay. Urgent medical help is required in all cases of suspected overdose.

The official management principle states that treatment is strictly symptomatic and supportive, as there is no specific antidote known for Praziquantel overdose. Interventions such as gastric lavage may be considered for recent ingestions to limit absorption. Intensive medical monitoring and prolonged hospital observation are required, especially when severe CNS symptoms are present, to ensure stability and recovery.

Therapeutic Uses of Cestocur

Cestocur is applied across domains where additional symptomatic support is needed in clinical settings marked by temporary physiological imbalance. The therapeutic category associated with Cestocur is generally used for managing symptoms associated with certain parasitic infections, such as those caused by schistosomiasis and clonorchiasis.

Relief for Acute Symptomatic Episodes

Cestocur may be part of symptomatic management in conditions characterized by periods of heightened symptoms or when symptoms appear suddenly and become more disruptive. It is commonly used to help with managing symptoms that interfere with daily comfort, providing a supportive therapeutic benefit when a patient requires additional assistance in symptom management. The drug's role is to contribute to easing the overall symptom load and assisting with maintaining functional stability during symptomatic periods.

Management of Intolerable Symptom Intensity

Cestocur plays a role in managing symptom clusters that may become intense or disruptive and create noticeable functional strain. By contributing to improved comfort during periods of heightened symptoms, this approach provides supportive relief when symptoms interfere with routine activities and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relevant for managing Symptoms That Interfere With Daily Functioning

Eligibility and Restrictions for Use

Cestocur (Praziquantel) is authorized for use in adults and children aged 1 year and older for its labeled indications. Safety and effectiveness of the medicine have not been established by regulatory authorities for use in children younger than 1 year of age. No special precautions are generally required for older adults.

Absolute Contraindications

Use of Cestocur is contraindicated and must not occur in the following populations:

  • Patients with known hypersensitivity or allergy to Praziquantel or any inactive component of the tablet.
  • Patients diagnosed with Ocular Cysticercosis (tapeworm infection within the eye), as parasite destruction may cause irreversible lesions.
  • Patients concurrently taking certain strong Cytochrome P450 (CYP) inducers, such as Rifampin, as this co-administration prevents the drug from reaching effective plasma levels.

Conditional Use and Restrictions

Caution and close monitoring are required for patients with moderate to severe hepatic impairment (liver dysfunction) due to the risk of higher and longer-lasting drug concentrations. Individuals with a history of epilepsy, seizures, or other signs of Central Nervous System (CNS) involvement should also use the medicine with care. For pregnant women, use is permitted only if clearly needed. Breastfeeding is not recommended on the day of treatment and for the subsequent 72 hours, as the drug is known to be excreted into breast milk.

What should I know about interactions with other medicines?

Cestocur Interactions with other medicines and products

This section outlines the officially documented interactions for Cestocur (Praziquantel), based on authoritative government regulatory documents.

Contraindicated Combinations

Co-administration with strong inducers of the Cytochrome P450 (CYP) enzyme system is formally prohibited. This is due to a significant risk of treatment failure caused by a drastic reduction in Praziquantel plasma concentrations. Agents in this category include Rifampin, several antiepileptic drugs (e.g., Phenytoin, Carbamazepine), and the herbal product St John's Wort.

Interaction Type Examples (Regulatory List) Implication on Praziquantel Exposure
Reduced Exposure (Strong CYP Induction) Rifampin, Phenytoin, Dexamethasone, St John's Wort Significant decrease in plasma levels
Increased Exposure (CYP Inhibition) Cimetidine, Itraconazole, Erythromycin Increased and prolonged plasma levels

Restrictions and Timing Requirements

When treating a patient currently on Rifampin, the strong inducer must be discontinued 4 weeks before Cestocur is administered. Treatment with Rifampin can be restarted one day following the final Cestocur dose.

Consumption of Grapefruit Juice is explicitly restricted, as it is documented to increase Praziquantel plasma concentrations. Separately, official labeling notes that patients with moderate to severe hepatic impairment may experience considerably higher and longer lasting plasma concentrations of unmetabolized Praziquantel due to reduced clearance.

Mechanism of Action

Molecular Mechanism: Calcium Influx and Parasite Paralysis

The action of Cestocur (Praziquantel) is initiated by its specific agonism at the parasitic flatworm’s unique Transient Receptor Potential Melastatin ( TRPM) ion channel ( TRPM PZQ). This high-affinity interaction instantly forces the channel open, causing a massive, uncontrolled influx of calcium ions ( Ca^2+) into the worm's cells. This fundamental molecular disruption triggers the primary physiological effect: immediate and sustained spastic paralysis of the parasite's musculature, resulting in loss of motor function.

️ Tegumental Damage and Immunological Processing

The severe Ca^2+ dysregulation not only causes paralysis but also swiftly damages its outer layer, the tegument, through vacuolization and eventual disintegration. This structural compromise exposes hidden parasite surface antigens, facilitating their recognition by host immune cells. This physiological cascade, sometimes enhanced by the drug's effect on host vascular tone (mesenteric vasoconstriction), supports the final systemic processing and removal of the parasite.

Dosage and Administration Information

How to Use Cestocur

The usage of Cestocur, which contains the active ingredient Praziquantel, is defined by specific administration principles intended to achieve the required therapeutic concentration rapidly. This medicine is administered solely via the oral route, typically as a film-coated tablet that is scored for ease of accurate dosage adjustment.


Official Administration Guidelines

Category Official Instruction
Route of administration Oral route only (by swallowing the tablet or its segments).
Dosing schedule Dose is calculated by body weight (mg/kg). Standard dosing is 20 mg/kg of body weight per administration for schistosomiasis.
Timing in relation to meals Must be taken during a meal (with food).
Frequency pattern Short-term, divided use: Three times a day (TID) on a single treatment day.

Procedural Usage Structure

The treatment course is generally administered as a single-day course, completed within 24 hours. The total daily dose is divided into three separate administrations, with each dose separated by an interval of 4 to 6 hours.

Tablets or their broken segments must be swallowed whole and promptly with water to mitigate the strong, bitter taste that can occur if the medication is held in the mouth. For patients who cannot swallow the tablets whole, they may be crushed or disintegrated and mixed with liquid or semi-solid food, though the resulting mixture must be ingested within one hour of preparation.

This protocol ensures a weight-adjusted dose is delivered three times a day during meals, a structure used for this anthelmintic therapy.

Recent Clinical Evidence

Research Evidence for Cestocur: Overview of Studies

The information below describes the structure of the research that has been conducted on Cestocur’s active ingredient, Praziquantel. It summarizes the types of studies, what was measured, and what remains unclear. This evidence contributes to the broader research landscape. Study results reflect the specific conditions under which they were conducted.

Evidence for Use in Schistosomiasis (Fluke Infections)

This section summarizes the structure of the extensive research base, which includes multi-decade Randomized Controlled Trials (RCTs) and systematic reviews, detailing what outcomes (such as parasite clearance and egg reduction rates) was studied for in the populations researched.

The research base involves numerous Randomized Controlled Trials (RCTs) and Systematic Reviews spanning decades. The key outcomes researched in these trials were the measurement of parasitological clearance, defined by the absence of parasite eggs, and the measurement of Egg Reduction Rates (ERR) in biological samples.

What remains uncertain is whether long-term effects are fully established, particularly concerning the prevention of late-stage chronic effects on organs. Research describes patterns related to lower measured activity against the parasite's juvenile forms, suggesting that evidence for treating the very early (acute) phase of infection is sparse.

Evidence for Use in Neurocysticercosis (Tapeworm Infections)

This part outlines the clinical trials, including those using combination regimens, that focused on specific radiological outcomes (like cyst resolution confirmed by imaging) and clinical measures like seizure frequency in adult patients.

Data show patterns related to Praziquantel being frequently evaluated as part of a multi-drug regimen, rather than predominantly as a single agent. The primary outcomes was studied for in these trials involved radiological clearance of the cysts, confirmed through brain imaging (CT or MRI). Follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes regarding long-term functional and seizure outcomes.

Key Studies & References

  1. WHO Model List of Essential Medicines (EML) for Treatment of taeniid cestode cysts (Neurocysticercosis) and Schistosomiasis

Frequently Asked Questions (FAQ)

Common questions about Cestocur (FAQ)


Q: Is Cestocur the same type of medicine as [similar drug name]?

A: Cestocur contains the active ingredient Praziquantel, which is classified as an anthelmintic drug. This pharmacological classification means it is officially used to treat parasitic flatworms, such as flukes and tapeworms. The definition of this drug is based on its unique chemical structure and its documented effects against these specific parasites.

Q: How quickly can a person expect Cestocur to start working?

A: According to official product information, Cestocur is absorbed quickly into the bloodstream, generally reaching its peak concentration one to three hours after the dose is administered. This is followed by a mechanism of action that is described as causing immediate effects upon the parasite's musculature.

Q: Is Cestocur available as a generic medicine?

A: Yes, Cestocur contains Praziquantel, which is the active substance. Praziquantel is also available as a generic version of the medicine for human use, in addition to its branded formulations.

Q: Is it true that Cestocur is a newer or older medication?

A: Praziquantel is considered an established medication in the field of antiparasitic therapy. It has been recognized for decades of use and has been included on the World Health Organization's Model List of Essential Medicines since 1979.

Q: Can Cestocur affect fertility, according to official warnings?

A: Official labeling provides guidance regarding the use of the drug during pregnancy and while breastfeeding. However, standard prescribing information does not contain specific formal statements or warnings regarding effects on human fertility or reproductive capability.

Q: What happens to the drug in the body over time (duration of action)?

A: The half-life of Praziquantel in the blood is relatively short, typically ranging from less than one hour to about one and a half hours for people with normal liver function. The half-life refers to the time it takes for half of the drug to be eliminated from the body.

Q: Is it necessary to have regular check-ups while on Cestocur?

A: The need for monitoring is documented based on a person's underlying health conditions. Close monitoring is specifically noted as being required for individuals with moderate to severe hepatic impairment (liver dysfunction), due to the risk of higher drug concentrations.

Q: What kind of research evidence supports the use of Cestocur?

A: The evidence base includes Randomized Controlled Trials and systematic reviews. Studies have primarily measured outcomes such as the reduction of parasite eggs in samples, known as Egg Reduction Rates, and the confirmation of cyst clearance through medical imaging.

Q: Why is Cestocur prescribed to some people and not others?

A: The choice is guided by official eligibility criteria. It is prescribed for specific parasitic flatworm infections in adults and children aged 1 year and older. However, the medicine is not authorized for use, or is contraindicated, in populations with known allergies to the drug, ocular cysticercosis, or those taking strong interacting medications like Rifampin.

Q: Is there a maximum length of time a person can be described Cestocur?

A: Cestocur is typically administered as a short-term treatment. For example, the recommended course for schistosomiasis is a one-day treatment with three divided doses. The total duration can vary from 1 to 30 days depending on the specific parasitic infection being treated, as defined in the official dosage guidelines.

Q: What are the most commonly discussed side effects of Cestocur online?

A: Documented common side effects (affecting up to 1 in 10 patients) include headache, dizziness, abdominal pain, nausea, vomiting, sleepiness (somnolence), fever, and general discomfort (malaise). Official descriptions state these effects are often transient (short-lived).

Q: Is it common to feel tired after starting Cestocur?

A: Yes, regulatory documents list 'somnolence' (sleepiness) as a common adverse reaction, affecting up to 1 in 10 patients. Asthenia, which is a feeling of weakness or lack of energy, is also documented but is listed as an uncommon effect (up to 1 in 100 patients).

Q: What is the typical age range of people who use Cestocur?

A: Cestocur is authorized for use in adults and children aged 1 year and older for its approved indications. Official regulatory bodies have not established its safety and effectiveness for use in children younger than 1 year of age.

Q: Does Cestocur have a risk of dependence or addiction?

A: No, Praziquantel, the active ingredient in Cestocur, is not officially classified as a controlled substance by major regulatory authorities like the U.S. Drug Enforcement Administration.

Q: Is Cestocur safe to use for people with pre-existing liver conditions?

A: Official labeling requires caution and close monitoring for people with moderate to severe liver dysfunction. This is because reduced liver function can lead to increased concentrations of the unmetabolized drug in the bloodstream. The constraints for use are outlined in the 'Who can and cannot use Cestocur' section.

Q: What happens if a person misses a dose of Cestocur?

A: Regulatory patient information advises taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to return to the regular dosing pattern. Regulatory patient information advises against taking a double dose to compensate for a missed one.

Q: Can Cestocur affect the results of common lab tests?

A: Official labeling notes that the medicine may result in a transitory and generally mild elevation of liver enzymes, known as transaminases. This is a temporary laboratory abnormality that may be observed in some patients.

Q: Why do some doctors choose Cestocur over similar alternatives?

A: Authoritative literature recognizes Praziquantel as the drug of choice for certain specific parasitic flatworm infections, including schistosomiasis and most foodborne trematode infections. This positioning is based on its documented effectiveness against these particular parasites.

Q: Is Cestocur known to cause changes in mood or behavior?

A: Official information mentions that the medicine can cause effects on the Central Nervous System (CNS), such as dizziness, headache, and sleepiness. It can also potentially worsen underlying CNS issues, such as epilepsy, in susceptible individuals.

Q: Do studies suggest Cestocur is more effective for certain subgroups of patients?

A: Studies have noted that the drug's effectiveness can vary based on the specific species of the parasite and the stage of infection being treated. Research frequently involves specific groups, such as school-aged children, particularly in areas where these infections are common.

Q: Can Cestocur be crushed or split if a person has trouble swallowing pills?

A: For patients who have difficulty swallowing, the tablets may be crushed or disintegrated and mixed with liquid or semi-solid food. However, official administration instructions define that the mixture should be ingested within one hour of its preparation, and the tablets should typically be swallowed whole to avoid the drug's bitter taste.

Q: Are there any known issues with stopping Cestocur suddenly?

A: Cestocur is typically prescribed as a short-term, single-day course of therapy, rather than a long-term treatment. Official documents do not contain specific warnings about adverse issues related to the sudden discontinuation of this short course of treatment.

Q: Do official documents mention anything about Cestocur causing hair loss?

A: Transient hair loss, medically termed alopecia, has been noted as a documented side effect in some safety reviews. Official safety reviews have recognized this effect, particularly in certain susceptible patient populations.

Q: What is the difference between a side effect and a drug interaction for Cestocur?

A: A side effect is an unintended bodily response to the medication itself, such as a headache or sleepiness. A drug interaction occurs when Cestocur's concentration in the body is altered, or the effects of the other drug are changed, because the two were taken together.

How should Cestocur be stored and disposed of?

The storage and disposal instructions for Cestocur (praziquantel) are mandatory requirements outlined in regulatory labeling to maintain the product's quality and ensure public safety.

Official Storage Requirements

Scope Item Official Regulatory Statement
Temperature Store at controlled room temperature or below 30 C; avoid excessive heat.
Protection Must be kept in the original container and protected from light and moisture.
Child Safety Must be kept out of the sight and reach of children.

Official Disposal Rules

Scope Item Official Regulatory Statement
Procedure Dispose of unused product according to local regulations for medicinal waste.
Restrictions Do not dispose of this medicine via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cestocur found in:

A-Z Index: